Compare Alliant Energy Corporation (LNT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Alliant Energy Corporation trades at $68.56 (market cap $17.69B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.7× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| LNT | REGN | |
|---|---|---|
Market Cap | $17.69B | $83.19B |
Sector | Utilities | Health |
52-Week High | $78.03 | $812.27 |
52-Week Low | $63.62 | $555.51 |
Enterprise Value | $29.78B | $77.90B |
Dividend Yield | 3.14% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $69.37, down 0.22% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of $0.65, beating expectations, and maintains strong fundamentals with 18.45% net income margin and 11.14% ROE. Recent news highlights mixed institutional activity and earnings performance influenced by data center demand and cost pressures.
The outlook is balanced with a consensus price target of $77.67 implying upside, supported by earnings beats and a clean energy investment plan. Risks include rising debt levels, cost inflation, and weather-related volatility. Analyst sentiment is positive with no sell ratings, but technical weakness warrants caution near-term.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
